Get access to our best features

Get access to our best features

Merck Germany Regains Exclusive Global Rights To Cancer Drug From Pfizer - Pfizer (NYSE:PFE), Merck (OTC:MKKGY)

Summary by Ground News
Merck KGaA regains exclusive rights to develop, manufacture, and commercialize Bavencio (avelumab) Pfizer will exit its global partnership over the PD-L1 MAb on 30 June. Pfizer shares are down 0.24% at $40.30 on the last check Monday.
Published 2 months ago · Germany

News Articles

More
Filters
All
Left
Center
Right
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

100% of the sources are Center
Benzinga
C 100%
See less detail